Determinants of Delayed Presentation and Advanced-Stage Diagnosis of Breast Cancer in Africa: A Systematic Review and Meta-Analysis.
Advanced-stage
Africa
Meta-analysis
breast cancer
delay
Journal
Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625
Informations de publication
Date de publication:
01 Apr 2021
01 Apr 2021
Historique:
received:
27
12
2020
entrez:
28
4
2021
pubmed:
29
4
2021
medline:
6
11
2021
Statut:
epublish
Résumé
Breast cancer (BC) mortality is exceptionally high in Africa due to late presentation and advanced-stage diagnosis. Previous studies examining barriers to early BC presentation are markedly inconsistent, showing conflicting findings within and between African regions, making resource allocation and designing interventional campaigns challenging. Our objective was to assess the strength or magnitude of the association between determinants/risk factors and delayed presentation/advanced-stage diagnosis of BC in Africa. Electronic searches in PubMed, AJOL, Google, ResearchGate, ScienceDirect, and PubMed Central found eligible articles between 2000 and 2020. The meta-analytical procedure in Meta-XL used the quality effect model. I-squared (I2) above 75% indicated high heterogeneity. The summary effect size was the odds ratio with 95% confidence intervals. The effect of socio-economic and demographic determinants on delay varies across African regions. Low level of education (1.63, 95% CI 1.01-2.63), and not performing breast self examination (BSE) (13.59, 95% CI 3.33-55.4) were significantly associated with delayed presentation. Younger patients had more significant delays in West Africa (WA, 1.41, 95%CI 1.08-1.85), and the reverse occurred in North Africa (0.68, 95%CI 0.48-0.97). Lack of BC knowledge (1.59, 95% CI 1.29-1.97), not performing BSE, or no history of undergoing clinical breast examination (CBE) (2.45, 95% CI 1.60-3.40), were associated with advanced-stage disease at diagnosis. Older patients had significantly more advanced disease in WA, and the reverse occurred in South Africa. Aggressive molecular BC subtypes [Triple negative (OR 1.62, 95% CI 1.27-2.06) or HER2 positive (1.56, 95% CI 1.10-2.23)] were significant determinants of advanced-stage diagnosis. Promoting early presentation and reducing advanced-stage BC throughout Africa should focus on modifiable factors, including providing quality education, improving breast health awareness and BC knowledge, and developing strategies to increase BSE and CBE. Interventions targeting socio-demographic determinants should be context-specific.
Sections du résumé
BACKGROUND/OBJECTIVE
OBJECTIVE
Breast cancer (BC) mortality is exceptionally high in Africa due to late presentation and advanced-stage diagnosis. Previous studies examining barriers to early BC presentation are markedly inconsistent, showing conflicting findings within and between African regions, making resource allocation and designing interventional campaigns challenging. Our objective was to assess the strength or magnitude of the association between determinants/risk factors and delayed presentation/advanced-stage diagnosis of BC in Africa.
METHODS
METHODS
Electronic searches in PubMed, AJOL, Google, ResearchGate, ScienceDirect, and PubMed Central found eligible articles between 2000 and 2020. The meta-analytical procedure in Meta-XL used the quality effect model. I-squared (I2) above 75% indicated high heterogeneity. The summary effect size was the odds ratio with 95% confidence intervals.
RESULTS
RESULTS
The effect of socio-economic and demographic determinants on delay varies across African regions. Low level of education (1.63, 95% CI 1.01-2.63), and not performing breast self examination (BSE) (13.59, 95% CI 3.33-55.4) were significantly associated with delayed presentation. Younger patients had more significant delays in West Africa (WA, 1.41, 95%CI 1.08-1.85), and the reverse occurred in North Africa (0.68, 95%CI 0.48-0.97). Lack of BC knowledge (1.59, 95% CI 1.29-1.97), not performing BSE, or no history of undergoing clinical breast examination (CBE) (2.45, 95% CI 1.60-3.40), were associated with advanced-stage disease at diagnosis. Older patients had significantly more advanced disease in WA, and the reverse occurred in South Africa. Aggressive molecular BC subtypes [Triple negative (OR 1.62, 95% CI 1.27-2.06) or HER2 positive (1.56, 95% CI 1.10-2.23)] were significant determinants of advanced-stage diagnosis.
CONCLUSION
CONCLUSIONS
Promoting early presentation and reducing advanced-stage BC throughout Africa should focus on modifiable factors, including providing quality education, improving breast health awareness and BC knowledge, and developing strategies to increase BSE and CBE. Interventions targeting socio-demographic determinants should be context-specific.
Identifiants
pubmed: 33906291
doi: 10.31557/APJCP.2021.22.4.1007
pmc: PMC8325140
pii:
doi:
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1007-1017Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Références
Rev Epidemiol Sante Publique. 2015 Jun;63(3):191-201
pubmed: 25975777
J Cancer Epidemiol. 2019 Aug 7;2019:2407138
pubmed: 31485229
Niger J Clin Pract. 2015 Jul-Aug;18(4):553-8
pubmed: 25966732
Br J Cancer. 2009 Dec 3;101 Suppl 2:S40-8
pubmed: 19956161
World J Surg Oncol. 2015 Jul 19;13:220
pubmed: 26187151
Br J Cancer. 2009 Dec 3;101 Suppl 2:S31-9
pubmed: 19956160
BMC Public Health. 2020 Jun 19;20(1):962
pubmed: 32560711
Eur J Cancer Prev. 2001 Feb;10(1):53-9
pubmed: 11263591
J Surg Res. 2019 Mar;235:181-189
pubmed: 30691793
Breast. 2012 Jun;21(3):416-8
pubmed: 22381153
Pan Afr Med J. 2016 May 13;24:63
pubmed: 27642404
Breast. 2011 Dec;20(6):555-61
pubmed: 21807518
PLoS One. 2017 Dec 6;12(12):e0187018
pubmed: 29211739
J Psychosom Res. 2005 Apr;58(4):321-6
pubmed: 15992567
Breast Cancer Res Treat. 2017 Feb;162(1):105-114
pubmed: 28025716
Breast. 2015 Dec;24(6):713-7
pubmed: 26371692
JAMA Oncol. 2017 Nov 1;3(11):1563-1567
pubmed: 28542677
Am J Surg. 2013 Apr;205(4):409-13
pubmed: 23375755
Lancet Oncol. 2013 Apr;14(4):363-70
pubmed: 23375833
BMC Public Health. 2009 Jun 30;9:213
pubmed: 19563685
J Glob Oncol. 2016 Jun 22;3(2):125-134
pubmed: 28717750
Cancer Causes Control. 2020 Apr;31(4):393-402
pubmed: 32124187
Malawi Med J. 2015 Mar;27(1):10-2
pubmed: 26137191
Ann Oncol. 2007 Jul;18(7):1172-6
pubmed: 17434897
Breast. 2012 Aug;21(4):428-34
pubmed: 22289154
Lancet Glob Health. 2020 Sep;8(9):e1203-e1212
pubmed: 32827482
Lancet Glob Health. 2016 Dec;4(12):e923-e935
pubmed: 27855871
Breast Cancer Res Treat. 2018 Jan;167(2):425-437
pubmed: 28951987
Pan Afr Med J. 2019 Oct 02;34:67
pubmed: 31819783
Ecancermedicalscience. 2017 Aug 30;11:763
pubmed: 28900476
Breast Dis. 2010;31(1):33-41
pubmed: 21109721
Mol Clin Oncol. 2015 Jul;3(4):785-788
pubmed: 26171180
J Glob Oncol. 2017 Mar 8;3(5):497-501
pubmed: 29094088
BMC Womens Health. 2018 Feb 14;18(1):40
pubmed: 29444670
Psychooncology. 2011 May;20(5):532-7
pubmed: 21456061
BMC Public Health. 2013 Oct 09;13:947
pubmed: 24107190
J Glob Oncol. 2019 Jul;5:1-8
pubmed: 31348736
Breast Care (Basel). 2008;3(1):17-20
pubmed: 20824015
Prev Med. 2011 Sep;53(3):118-20
pubmed: 21596057
BMC Cancer. 2017 Dec 1;17(1):804
pubmed: 29191181
PLoS One. 2018 Feb 2;13(2):e0192071
pubmed: 29394271
BMC Res Notes. 2015 Sep 22;8:467
pubmed: 26395344
Oncologist. 2015 Jul;20(7):780-8
pubmed: 26032138
Asian Pac J Cancer Prev. 2008 Oct-Dec;9(4):703-7
pubmed: 19256763
PLoS One. 2019 Mar 20;14(3):e0212806
pubmed: 30893313
Ethiop J Health Sci. 2013 Jul;23(2):150-7
pubmed: 23950631
Medicine (Baltimore). 2019 Oct;98(40):e17454
pubmed: 31577773
JAMA. 2015 Jan 13;313(2):165-73
pubmed: 25585328
BMC Womens Health. 2017 Jan 9;17(1):3
pubmed: 28068979
J Egypt Natl Canc Inst. 2010 Dec;22(4):209-15
pubmed: 21863072
BMJ Open. 2019 Nov 11;9(11):e032228
pubmed: 31719089
BMC Res Notes. 2012 Aug 21;5:452
pubmed: 22909280
PLoS One. 2018 Nov 29;13(11):e0207928
pubmed: 30496219
BMC Clin Pathol. 2015 Jul 09;15:14
pubmed: 26161039
Ann Epidemiol. 2017 Oct;27(10):659-671.e7
pubmed: 29128086
J Glob Oncol. 2019 Jul;5:1-10
pubmed: 31322993
Br J Med Med Res. 2014 May 1;4(13):2599-2610
pubmed: 25984460
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Int J Cancer. 2018 Apr 15;142(8):1568-1579
pubmed: 29197068
Cancer Causes Control. 2017 Jul;28(7):685-697
pubmed: 28447308
Comp Educ Rev. 2010 May;54(2):295-319
pubmed: 26448653
J Public Health (Oxf). 2016 Sep;38(3):591-598
pubmed: 26359315